Can IV Infusions Of Bone Marrow Derived Mesenchymal Stem Cell Extracellular Vesicles Be The Fountain Of Youth?

Abstract

There is increasing published literature to support the safety and efficacy of IV infusions of bone marrow-derived expanded allogeneic mesenchymal stem cells (MSCs) for the treatment of various auto-immune diseases. Frailty Syndrome was created to provide a way of objectively measuring aging with physical activity scales and bio-inflammatory markers. IV infusions of allogeneic MSCs have been reported to statistically significantly increase physical function and decrease inflammatory biomarkers in Frailty Syndrome. Replacing cellular allogeneic IV infusions with acellular bone marrow-derived MSC extracellular vesicle isolate products (EVIP) containing active growth factors (GFs) and exosomes has numerous advantages. Regenerative medicine researchers and clinicians now realize that living MSCs are not required to achieve clinical efficacy. The clinical efficacy of MSCs is due to their paracrine release of GFs and exosomes. Living MSCs are not required to accomplish the paracrinesignaling of GFs and exosomes. Acellular MSC EVIP containing active GFs and exosomes are the future of regenerative medicine.Acellular exosomesderived from bone marrow MSCs provide a consistent product that has extensive characterization, which includes advanced particle analysis, proteomic evaluation and USP<71> sterility assurance. The future “Fountain of Youth” will be the frequent (3 to 4 times per year) IV infusion of bio pharmacologic quality bone marrow-derived MSC EVIP. These active GF and exosome infusions will result in a continual down regulation of systemic inflammation and based on published research reverse many of the inflammatory effects of aging.